Skip to main content

Table 1 Patient characteristics

From: A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation

Characteristics Training cohort (n = 335) Validation cohort (n = 135) P value
Median age at allo-HSCT, years (range) 28 (1–66) 31 (1–64) 0.596
Gender, n (%) 0.635
 Male 198 (59.1) 83 (61.5)  
 Female 137 (40.9) 52 (38.5)  
Underlying disease, n (%) 0.704
 Acute myeloid leukemia 187 (55.8) 78 (57.8)  
 Acute lymphoblastic leukemia 143 (42.77) 55 (40.7)  
 Mixed-phenotype acute leukemia 5 (1.55) 2 (1.5)  
Disease status before allo-HSCT, n (%) 0.535
 CR1 321 (95.8) 131 (97.0)  
 > CR1 14 (4.2) 4 (3.0)  
Disease risk index before allo-HSCT, n (%) 0.714
 Low and intermediate risk 268 (80.0) 110 (81.5)  
 High and very high risk 67 (20.0) 25 (18.5)  
Donor/recipient relation, n (%) 0.379
 Mother donor 26 (7.8) 12 (8.9)  
 Collateral donor 12 (3.6) 0 (0.0)  
 Others 297 (88.7) 123 (91.1)  
Donor/recipient gender matched, n (%) 0.258
 Female donor/male recipient combination 57 (17.0) 29 (21.5)  
 Others 278 (83.0) 106 (78.5)  
HCT-CI scores before allo-HSCT, n (%) 0.121
 0 (Low-risk) 237 (70.7) 105 (77.8)  
 1–2 (Intermediate-risk) 74 (22.1) 23 (17.0)  
 ≥ 3 (High-risk) 24 (7.2) 7 (5.2)  
Median donor age at allo-HSCT, years (range) 40 (9–70) 36 (10–63) 0.094
Cytomegalovirus serostatus before HSCT, n (%) 0.501
 Donor +/recipient + 312 (93.1) 128 (94.8)  
 Donor +/recipient − 11 (3.3) 3 (2.2)  
 Donor −/recipient +  10 (3.0) 4 (3.0)  
 Donor −/recipient − 2 (0.6) 0 (0.0)  
Number of HLA-A, HLA-B, HLA-DR mismatches, n (%) 0.914
 1 Locu 8 (2.4) 3 (2.2)  
 ≥ 2 Loci 327 (97.6) 132 (97.8)  
Blood group compatibility, n (%) 0.719
 Matched 175 (52.2) 73 (54.1)  
 Mismatched 160 (47.8) 62 (45.9)  
Conditioning regimen, n (%) 0.350
 Chemotherapy-based regimen 325 (97.0) 133 (98.5)  
 TBI-based regimen 10 (3.0) 2 (1.5)  
Cell type, median count (range)
 MNC counts (× 108/kg) 9.2 (4.4–27.3) 9.3 (4.2–27.5) 0.218
 CD34+ cell counts (× 106/kg) 3.8 (0.7–25.33) 3.9 (1.1–29.4) 0.572
 CD3+ cell counts (× 106 kg) 340.9 (116.2–874.2) 352.0 (170.4–1172.2) 0.617
 CD4+ cell counts (× 106/kg) 182.5 (68.3–600.1) 184.7 (75.2–492.7) 0.688
 CD8+ cell counts (× 106/kg) 126.7 (29.6–347.9) 128.0 (46.1–1511.2) 0.559
 CD14+ cell counts (× 106/kg) 211.3 (73.3–1065.0) 215.6 (95.8–716.9) 0.373
 CD8+/CD3+ cells ratio 0.4 (0.2–0.7) 0.4 (0.1–1.3) 0.817
 CD4+/CD8+ cells ratio 1.5 (0.4–4.7) 1.5 (0.3–3.0) 0.672
 CD4+/CD3+ cells ratio 0.6 (0.2–0.8) 0.5 (0.1–0.7) 0.627
 CD3+/CD14+ cells ratio 1.6 (0.6–4.4) 1.5 (0.6–3.7) 0.601
Median follow-up of survivors, days (range) 203 (62–490) 192 (52–509) 0.134
  1. allo-HSCT, allogeneic hematopoietic stem cell transplantation; CR, complete remission; HLA, human leukocyte antigen; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; MNC, mononuclear cells; TBI, total body irradiation